Table 2.

Cytotoxic effect of NU6140 against OAW42 and OAW42/Surv cells as single agent and in combination with paclitaxel

Agent/combinationConcentrationSurviving fraction
Expected/observed ratio*CI
ObservedExpected
A. OAW42/e
    Paclitaxel (nmol/L)10.81
2.50.56
50.14
    NU6140 (μmol/L)10.83
2.50.29
50.17
    Paclitaxel (nmol/L) + NU6140 (μmol/L)1
10.820.672.091.33
2.5
2.50.080.162.000.57
5
50.00230.023100.36
    NU6140 (μmol/L) + paclitaxel (nmol/L)1
10.430.671.550.95
2.5
2.50.130.161.230.74
5
50.0140.0231.640.60
B. OAW42/Surv
    Paclitaxel (nmol/L)10.99
50.75
    NU6140 (μmol/L)10.89
2.50.30
50.18
    Paclitaxel (nmol/L) + NU6140 (μmol/L)1
10.850.881.031.19
2.5
2.50.300.270.901.28
5
50.160.130.811.34
    NU6140 (μmol/L) + paclitaxel (nmol/L)1
10.870.881.011.25
2.5
2.50.320.270.841.33
5
50.180.130.721.40
  • * (Surviving fraction observed) / (surviving fraction expected).

  • CI according to Chou and Talalay (ref. 30).

  • Calculated as the product of the surviving fractions observed for individual drugs.